Abstracts

979 – Cabotegravir LA for PrEP: Progress in HIV Prevention From 3 Years of OPERA Data

Background Cabotegravir long-acting (CAB LA) is the first FDA-approved injectable for HIV pre-exposure prophylaxis (PrEP). This analysis evaluated CAB-LA usage, adherence to its dosing schedule, and the incidence of HIV acquisition in routine clinical care. Methods Adults without HIV receiving ≥1 CAB LA PrEP injection between 21Dec2021 and 30Jun2024 in the US OPERA cohort were followed…

449 – Peripheral Endothelial Glycocalyx Degeneration Is Associated With White Matter Compromise in HIV

Background The endothelial glycocalyx plays a major role in maintaining the blood-brain barrier (BBB) and vascular health. Injury to the endothelial glycocalyx, often seen in infectious or inflammatory conditions, may disrupt BBB function. Two markers of glycocalyx degradation, hyaluronic acid (HA) and syndecan-1, were examined for associations with brain structure with a view to understanding…

240 – Low-Dose Methamphetamine (MA) Triggers Inflammasome Activation in MA-Naive People With HIV on ART

Background Substance use disorders (SUD) adversely affect the prognosis of people with HIV (PWH) by impairing immune responses, reducing adherence to antiretroviral therapy (ART), and increasing the burden of comorbidities. Our previous findings showed that methamphetamine (MA) exposure in PWH under ART was associated with activation of the inflammasome cascade in both innate and adaptive…

812 – PrEP Use Trajectories Among Women Initiating PrEP in Pregnancy

Background Understanding patterns of oral HIV PrEP use after initiation in pregnancy could guide adherence support throughout the perinatal period. Methods We analyzed data from a randomized trial conducted in Western Kenya between February 2022 and September 2024 (NCT04472884). The trial enrolled pregnant women initiating daily oral HIV PrEP in routine antenatal clinics and followed…

287 – Mutation-Constrained Regions of HIV-1 Proteins Elicit Antigen-Specific Effector CD8 T-Cell Responses

Background HIV-1-specific CD8 T cell responses directed against genetically-conserved HIV-1 protein regions are associated with viral control. Therefore, we developed the Immunoinformatics Analysis Pipeline (IMAP) to identify 182 peptides (IMAP-peptides) from 5 HIV-1 protein regions (Gag, Pol, Vif, Vpr, and Env) which are mutation-constrained, genetically-conserved across global HIV-1 subtypes, and predicted to bind common HLA-1 alleles providing 99%…

317 – Effectiveness of Messenger RNA–Based Vaccines Among People With HIV: A Case-Control Study

Background In people living with HIV (PLWH), persistent immune activation remains despite virologic suppression with antiretroviral therapy, thereby reducing vaccine effectiveness. Current guidelines recommend strengthened and individualized vaccination strategies, with viral suppression and immune reconstitution as essential prerequisites. The aim of the study is to evaluate whether chronic HIV infection may also impact the effectiveness of the…

324 – Comparison of Subcutaneous Versus Intradermal Administration of MVA Vaccine Booster Dose

Background MVA-BN vaccination is now considered the primary preventive measure against mpox infection. A booster dose administered at least two years after the primary vaccination significantly enhances both humoral and cellular immunity. Assessing whether the subcutaneous (SC) or intradermal (ID) administration route influences the magnitude of the response may inform public health strategies for maximizing…

363 – IL-1β Blockade Reprograms Antiviral Immunity and CD8+ T-Cell Responses to Reduce the HIV Reservoir

Background Chronic inflammation contributes to immune dysregulation in people with HIV (PWH), even during suppressive antiretroviral therapy (ART). While IL-1b is a key inflammatory mediator, its blockade has not been mechanistically studied in this context. We investigated the immunologic effects of IL-1b inhibition using Canakinumab (Cana), a monoclonal antibody targeting IL-1b, in ART-suppressed PWH. Methods…